Literature DB >> 10478167

Tuberculosis: 9. Treatment.

E Hershfield1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10478167      PMCID： PMC1230544     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  27 in total

1.  Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

Authors:  N Kennedy; L Berger; J Curram; R Fox; J Gutmann; G M Kisyombe; F I Ngowi; A R Ramsay; A O Saruni; N Sam; G Tillotson; L O Uiso; M Yates; S H Gillespie
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

2.  Twenty isoniazid-associated deaths in one state.

Authors:  T S Moulding; A G Redeker; G C Kanel
Journal:  Am Rev Respir Dis       Date:  1989-09

3.  Tracheobronchopathia osteochondroplastica presenting as right middle lobe collapse. Diagnosis by bronchoscopy and computerized tomography.

Authors:  M K Hodges; E Israel
Journal:  Chest       Date:  1988-10       Impact factor: 9.410

Review 4.  Update on rifampin drug interactions. II.

Authors:  S M Borcherding; A M Baciewicz; T H Self
Journal:  Arch Intern Med       Date:  1992-04

5.  In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis.

Authors:  W W Yew; S Y Kwan; W K Ma; M A Khin; P Y Chau
Journal:  J Antimicrob Chemother       Date:  1990-08       Impact factor: 5.790

6.  Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin.

Authors:  E Cambau; W Sougakoff; M Besson; C Truffot-Pernot; J Grosset; V Jarlier
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

7.  Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

Authors:  N Kennedy; R Fox; G M Kisyombe; A O Saruni; L O Uiso; A R Ramsay; F I Ngowi; S H Gillespie
Journal:  Am Rev Respir Dis       Date:  1993-12

8.  Emergence of fluoroquinolone-resistant tuberculosis in New York City.

Authors:  E A Sullivan; B N Kreiswirth; L Palumbo; V Kapur; J M Musser; A Ebrahimzadeh; T R Frieden
Journal:  Lancet       Date:  1995-05-06       Impact factor: 79.321

9.  Ethambutol kinetics in patients with impaired renal function.

Authors:  A Varughese; D C Brater; L Z Benet; C S Lee
Journal:  Am Rev Respir Dis       Date:  1986-07

10.  Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months.

Authors:  J H Perriëns; M E St Louis; Y B Mukadi; C Brown; J Prignot; F Pouthier; F Portaels; J C Willame; J K Mandala; M Kaboto
Journal:  N Engl J Med       Date:  1995-03-23       Impact factor: 91.245
View more
  6 in total

Review 1.  Tuberculosis: 10. Prevention.

Authors:  D Menzies; T N Tannenbaum; J M FitzGerald
Journal:  CMAJ       Date:  1999-09-21       Impact factor: 8.262

Review 2.  Tuberculosis: 11. Nosocomial disease.

Authors:  K Schwartzman; D Menzies
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

Review 3.  Tuberculosis: 13. Control of the disease among aboriginal people in Canada.

Authors:  J M FitzGerald; L Wang; R K Elwood
Journal:  CMAJ       Date:  2000-02-08       Impact factor: 8.262

Review 4.  Tuberculosis: 12. Global disease and the role of international collaboration.

Authors:  D A Enarson
Journal:  CMAJ       Date:  2000-01-11       Impact factor: 8.262

5.  Can you get tuberculosis twice?

Authors:  John Hoey
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

6.  Latent tuberculosis: revised treatment guidelines.

Authors:  Erica Weir; David N Fisman
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.